Skip to main content
. Author manuscript; available in PMC: 2020 Jul 7.
Published in final edited form as: Int J Obes (Lond). 2020 Jan 7;44(4):948–963. doi: 10.1038/s41366-019-0512-z

Fig. 1.

Fig. 1.

Expression of liver CYP1B1 in AHR-based obesity. (A) Male B6 mice (n=4 mice per experimental group) were fed control and Western diets with and without aNF (~90 mg/kg/day) ad libitum for 40 weeks beginning at weaning. (B) Mean body mass gain of each experimental group at week 40. (C) Consumption of food per mouse for each experimental group (n=4). (D) Liver mass/body mass ratios were determined by weighing at the conclusion of the 40-week diet regimen. (E) Representative liver sections (n=3) stained with hematoxylin and eosin (40X magnification). (F) Total RNA isolated from liver was subjected to microarray analysis. (G) Proteins isolated from liver at termination were resolved by Western blotting. Vinculin served as a loading control (n=3). (H) Representative sections of liver tissue (n=3) stained with anti-CYP1B1 antibody at termination of the 40-week diet regimen (50X magnification) with inset (200X magnification) showing a central vein. p-value: *, ≤0.05; **, ≤0.01; ***, ≤0.001. Error bars represent standard error of means (SEM).